SNOA · Sonoma Pharmaceuticals, Inc. · Metrics
Market Cap
$5.51M
Shares
4.79M
Volume · Oct 23
40.27K
Avg daily vol (3M)
105.51K
SNOA metrics
82 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$1.11
Market cap
$5.51M
Price action
20 metricsPrice change (1W)
+0.0%
Price change (30D)
-8.0%
Price change (3M)
-0.9%
Price change (6M)
-36.1%
Price change (YTD)
-68.4%
Price change (1Y)
-68.8%
Trailing year
Price change (5Y)
—
52-week high
$4.00
52-week low
$1.01
Change from 52-week high
-71.3%
Change from 52-week low
+13.9%
Annualized volatility
71.8%
Annualized volatility (3M)
58.3%
Beta
1.2
RSI (14D)
40.8
Price vs SMA 50
-9.0%
Price vs SMA 200
-35.3%
Avg volume (3M)
105,112
Relative volume
0.2
Average dollar volume
$135,895
Company
3 metricsSector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
4.79M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.2×
reciprocal yield 401.6%
P / book
0.8
reciprocal yield 120.8%
FCF yield
-48.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-41.5%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
0.6×
reciprocal yield 181.8%
EV / revenue historical average (5Y)
0.6×
reciprocal yield 181.8%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
38.9%
Operating margin
-6.4%
Trailing 12 months
Net margin
-10.3%
Gross profit (TTM)
$8.53M
Operating profit (TTM)
−$1.41M
Net income (TTM)
−$2.26M
Trailing 12 months
Diluted EPS (TTM)
$-1.22
FCF margin
-12.1%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+59.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$21.92M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+134.4%
Year over year · more shares
Revenue CAGR (3Y)
+13.7%
Revenue CAGR (5Y)
+0.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-34.3%
Return on assets
-12.5%
Debt / equity
—
Current ratio
3.0
EBITDA (TTM)
−$1.27M
Free cash flow (TTM)
−$2.65M
Quick ratio
2.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$5.34M
Total assets
$18.11M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$2.57M
Capital expenditures (TTM)
$88,000
R&D (TTM)
$2.27M
SG&A (TTM)
$7.66M
Stock compensation (TTM)
$256,000
R&D / revenue
10.4%
Stock compensation / revenue
1.2%
Ownership (13F)
9 metrics13F filers
14
13F filer change QoQ
-3
Institutional ownership
2.3%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
0.8%
Private-fund adviser ownership
0.8%
Active holders' share change QoQ
+127.9%
Holder tenure
3.8
Price vs estimated holder cost
-41.3%
Ownership (registered funds)
1 metricsIndex-fund ownership
0.8%
Short interest
3 metricsShort interest
3.4%
Latest settlement · 3.1 days to cover
Days to cover
3.1d
Short-squeeze score
37 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—